Share the post "The Impact of Global Events of Foriegn Investments on 10 Jul 2024"
| Comapny Logo | Company | Client name | Buy/Sell | Qty Traded | Price | Trader Name |
|---|---|---|---|---|---|---|
 |
FSN E-Commerce Ventures Limited | Canada Pension Plan Investment Board | SELL | 14M | 174.04 | Na |
The 14M shares of FSN E-Commerce Ventures Limited have been sold by the by Canada Pension Plan Investment Board through Foriegn Investments at a price of ₹174.04 per share.
| Company Logo | Company | Client name | Buy/Sell | Qty Traded | Price | Trader Name |
|---|---|---|---|---|---|---|
 |
Delhivery Limited | Aditya Birla Sun Life Mutual Fund | BUY | 2M | 388.45 | Canada Pension Plan Investment Board |
 |
Mankind Pharma Limited | Aurigin Master Fund Limited | BUY | 48K | 2082.00 | Hema Cipef (i) Limited |
|
Delhivery Limited | Blackstone Aqua Master Sub-fund | BUY | 257K | 388.45 | Canada Pension Plan Investment Board |
|
Delhivery Limited | Bofa Securities Europe Sa | BUY | 296K | 388.45 | Canada Pension Plan Investment Board |
|
Delhivery Limited | Canada Pension Plan Investment Board | SELL | 257K | 388.45 | Hsbc Indian Equity Mother Fund |
|
Mankind Pharma Limited | Citigroup Global Markets Mauritius Private Limited (odi) | BUY | 48K | 2082.00 | Hema Cipef (i) Limited |
|
Delhivery Limited | Copthall Mauritius Investment Limited | BUY | 1M | 388.45 | Canada Pension Plan Investment Board |
|
Delhivery Limited | Ghisallo Master Fund Lp | BUY | 875K | 388.45 | Canada Pension Plan Investment Board |
|
Mankind Pharma Limited | Goldman Sachs (singapore) Pte | BUY | 48K | 2082.00 | Hema Cipef (i) Limited |
|
Delhivery Limited | Hsbc Global Investment Funds Indian Equity | BUY | 256K | 388.45 | Canada Pension Plan Investment Board |
|
Delhivery Limited | Hsbc Indian Equity Mother Fund | BUY | 142K | 388.45 | Canada Pension Plan Investment Board |
|
Delhivery Limited | Hsbc Indien | BUY | 67K | 388.45 | Canada Pension Plan Investment Board |
|
Delhivery Limited | Morgan Stanley Asia Singapore Pte | BUY | 1M | 388.45 | Canada Pension Plan Investment Board |
|
Mankind Pharma Limited | National Pension Service | BUY | 37K | 2082.00 | Hema Cipef (i) Limited |
|
Delhivery Limited | Optimas Global Alpha Fund | BUY | 257K | 388.45 | Canada Pension Plan Investment Board |
|
Mankind Pharma Limited | Pggm World Equity Ii B.v. | BUY | 10K | 2082.00 | Hema Cipef (i) Limited |
|
Mankind Pharma Limited | Pictet – Indian Equities | BUY | 321K | 2082.00 | Hema Cipef (i) Limited |
|
Delhivery Limited | Societe Generale | BUY | 260K | 388.45 | Canada Pension Plan Investment Board |
|
Delhivery Limited | Verition Multi-strategy Master Fund Ltd. | BUY | 257K | 388.45 | Canada Pension Plan Investment Board |
Delhivery Limited shares totaling 2M were purchased by the by Aditya Birla Sun Life Mutual Fund of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share. Mankind Pharma Limited shares totaling 48K were purchased by the by Aurigin Master Fund Limited of Foriegn Investments, with the transaction occurring at a price of ₹2082.00 per share. Subsequently, the shares were sold by Hema Cipef (i) Limited at the same price per share. Delhivery Limited shares totaling 257K were purchased by the by Blackstone Aqua Master Sub-fund of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share.
Delhivery Limited shares totaling 296K were purchased by the by Bofa Securities Europe Sa of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share. Delhivery Limited shares totaling 257K were sold by the by Canada Pension Plan Investment Board of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were purchased by Hsbc Indian Equity Mother Fund at the same price per share. Mankind Pharma Limited shares totaling 48K were purchased by the by Citigroup Global Markets Mauritius Private Limited (odi) of Foriegn Investments, with the transaction occurring at a price of ₹2082.00 per share. Subsequently, the shares were sold by Hema Cipef (i) Limited at the same price per share.
Delhivery Limited shares totaling 1M were purchased by the by Copthall Mauritius Investment Limited of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share. Delhivery Limited shares totaling 875K were purchased by the by Ghisallo Master Fund Lp of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share. Mankind Pharma Limited shares totaling 48K were purchased by the by Goldman Sachs (singapore) Pte of Foriegn Investments, with the transaction occurring at a price of ₹2082.00 per share. Subsequently, the shares were sold by Hema Cipef (i) Limited at the same price per share.
Delhivery Limited shares totaling 256K were purchased by the by Hsbc Global Investment Funds Indian Equity of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share. Delhivery Limited shares totaling 142K were purchased by the by Hsbc Indian Equity Mother Fund of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share. Delhivery Limited shares totaling 67K were purchased by the by Hsbc Indien of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share.
Delhivery Limited shares totaling 1M were purchased by the by Morgan Stanley Asia Singapore Pte of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share. Mankind Pharma Limited shares totaling 37K were purchased by the by National Pension Service of Foriegn Investments, with the transaction occurring at a price of ₹2082.00 per share. Subsequently, the shares were sold by Hema Cipef (i) Limited at the same price per share. Delhivery Limited shares totaling 257K were purchased by the by Optimas Global Alpha Fund of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share.
Mankind Pharma Limited shares totaling 10K were purchased by the by Pggm World Equity Ii B.v. of Foriegn Investments, with the transaction occurring at a price of ₹2082.00 per share. Subsequently, the shares were sold by Hema Cipef (i) Limited at the same price per share. Mankind Pharma Limited shares totaling 321K were purchased by the by Pictet – Indian Equities of Foriegn Investments, with the transaction occurring at a price of ₹2082.00 per share. Subsequently, the shares were sold by Hema Cipef (i) Limited at the same price per share. Delhivery Limited shares totaling 260K were purchased by the by Societe Generale of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share.
Delhivery Limited shares totaling 257K were purchased by the by Verition Multi-strategy Master Fund Ltd. of Foriegn Investments, with the transaction occurring at a price of ₹388.45 per share. Subsequently, the shares were sold by Canada Pension Plan Investment Board at the same price per share.
FSN E-Commerce Ventures Limited
16.00
Net Sales
90.71
Net Profit
16.00
Total Income
-16.00
Expenditure
218
Current Price
62,244
Market Cap
The latest financial figures for FSN E-Commerce Ventures Limited indicate a strong performance. The company achieved net sales of ₹16.00 million and total income of ₹16.00 million for the quarter. Expenditure was ₹-16.00 million, resulting in a net profit of ₹90.71 million. Earnings per Share (EPS) for continuing operations stood at ₹0.02. The report also shows other income of ₹70.63 million, finance costs of ₹-211.34 million, and employee benefit expenses of ₹-1.00 million. Depreciation and amortization expenses totaled ₹-596.49 million. Current tax expense was ₹-306.28 million and deferred tax expense was ₹208.03 million. Total comprehensive income for the period was ₹98.54 million, with other comprehensive income net of taxes at ₹7.83 million.
With a market capitalization of ₹62,244 crore, the company’s stock is currently priced at ₹218. The historical trading range of the stock is ₹230 / 136. The P/E ratio is remarkably high at 1,612, suggesting a significant valuation. The book value stands at ₹4.42, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is 6.87%, and the Return on Equity (ROE) is 2.44%. The debt-to-equity ratio is very low at 0.77, though the company shows a negative net cash flow of ₹34.4 crore. The Piotroski score is 5.00, with the Graham Number pegged at ₹3.67. The Price-to-Book (P/B) ratio of 49.3 highlights a premium valuation.
Delhivery Limited
21,723.04
Net Sales
543.59
Net Profit
22,822.16
Total Income
22,228.88
Expenditure
415
Current Price
30,656
Market Cap
In the most recent financial analysis for Delhivery Limited, key metrics demonstrate a solid performance. The net sales reached ₹21,723.04 million, with total income amounting to ₹22,822.16 million. Expenditure was recorded at ₹22,228.88 million, resulting in a net profit of ₹543.59 million. EPS figures for continuing operations are ₹0.74. Other notable figures include other income of ₹1,099.12 million, finance costs of ₹282.23 million, and employee benefit expenses totaling ₹3,328.37 million. Depreciation and amortization expenses were ₹1,194.25 million, with current tax at ₹0.00 million and deferred tax at ₹-13.84 million. The total comprehensive income for the period was ₹537.08 million, and other comprehensive income net of taxes was ₹-6.51 million.
With a market capitalization of ₹30,656 crore, the company’s stock is currently priced at ₹415. The historical trading range of the stock is ₹488 / 354. The P/E ratio is remarkably high at , suggesting a significant valuation. The book value stands at ₹124, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is -1.73%, and the Return on Equity (ROE) is -2.94%. The debt-to-equity ratio is very low at 0.13, though the company shows a negative net cash flow of ₹7.54 crore. The Piotroski score is 5.00, with the Graham Number pegged at ₹. The Price-to-Book (P/B) ratio of 3.34 highlights a premium valuation.
Mankind Pharma Limited
28,934.20
Net Sales
5,430.70
Net Profit
29,940.20
Total Income
23,303.10
Expenditure
2,424
Current Price
97,116
Market Cap
For Mankind Pharma Limited, the latest financial data showcases impressive results. The company reported net sales of ₹28,934.20 million and total income of ₹29,940.20 million for the quarter. Expenditure was ₹23,303.10 million, resulting in a net profit of ₹5,430.70 million. EPS for continuing operations was ₹13.39. Additional financial details include other income of ₹1,006.00 million, finance costs of ₹109.10 million, and employee benefit expenses of ₹6,337.80 million. Depreciation and amortization expenses were ₹1,077.40 million. Current tax was ₹1,387.00 million and deferred tax amounted to ₹-141.50 million. Total comprehensive income for the period was ₹5,399.70 million, with other comprehensive income net of taxes at ₹-31.00 million.
The company's market cap is ₹97,116 crore, with a stock price of ₹2,424. The historical stock range has been between ₹2,556 / 1,683. Its Price-to-Earnings (P/E) ratio of 49.4 indicates a high valuation. The book value per share is ₹234, and it has a dividend yield of 0.00%. The ROCE is 26.2% and ROE is 21.5%. With a very low debt-to-equity ratio of 0.02, the company is minimally leveraged. However, it reports a negative net cash flow of ₹77.2 crore. The Piotroski score of 9.00 and the Graham Number of ₹508 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 10.4 suggests the stock is trading at a premium.
